Statera BioPharma Inc (STAB)

[NeilWaterson]

The company has advanced research activities that builds upon its STAT-200 platform to improve drug characteristics and clinical benefit beyond opioid receptors.

$STAB is going to be a biotech POWERHOUSE.

Quote:
$STAB is aggressive on opioid treatment research. Perfect timing for the PERFECT STORM >>
The research is based on the discovery that STAT-200, which originally was designed to antagonize opioid receptors, modulates multiple signaling pathways through receptors known as TLRs. These receptors act as master controllers of inflammation. Statera’s discovery platform identifies novel compositions that build upon STAT-200 by modulating multiple cellular targets, versus one, to restore cellular homeostasis. These findings have led to the selection of promising new compositions with the potential to treat a range of inflammatory-related diseases.